AVLN logo

AVALYN PHARMA INC

AVLNNASDAQ
🏆 #2322 by market capUS Equity
$27.17▼ $1.15 (−4.25%)
After hours · at close
🔔
Track AVLN
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 4.3%
7d▼ 16.3%
14d▼ 20.7%
30d▼ 21.6%
ytd—
1y—
🏦Market Cap
$1.20B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
68
Fair

Trading Snapshot

Day Range
$27.05 – $27.37
52-Week Range
$24.15 – $40.17
Volume
$2.60B
Avg Volume
$1.90B
Shares Outstanding
44.3M
Next Earnings
Dec 3, 2026

Fundamentals Snapshot

Annual Revenue
$124M
Last Q Revenue
$32M
P/E Ratio
-22.0
P/S Ratio
0.0x
EPS (TTM)
$-1.26
Dividend Yield
0.00%

Why Investors Own AVLN

  • ✓High-growth profile — revenue up +46.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 80% gross margin and 8% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AVLN logo

AVALYN PHARMA INC

AVLN
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$124M▲ +50.9% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
79.9%▲ +3.7% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$32M▲ +50.9% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$10M▲ +50.9% YoY
StockOtter · stockotter.space

About AVALYN PHARMA INC

Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$35.14
▲ +29.4% Upside
High Target$41.88
Low Target$32.92
Based on 27 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

AVALYN PHARMA INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift AVLN price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

AVALYN PHARMA INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.